Cargando…

News from the Cold Chamber: Clinical Experiences of POLARx versus Arctic Front Advance for Single-Shot Pulmonary Vein Isolation

Cryoballoon (CB)-guided pulmonary vein isolation (PVI) represents a cornerstone in the treatment of atrial fibrillation (AF). Recently, a novel balloon-guided single shot device (POLARx, Boston Scientific) was designed. Our study aimed to compare the efficacy, safety and characteristics of the novel...

Descripción completa

Detalles Bibliográficos
Autores principales: Guckel, Denise, Lucas, Philipp, Isgandarova, Khuraman, El Hamriti, Mustapha, Bergau, Leonard, Fink, Thomas, Sciacca, Vanessa, Imnadze, Guram, Braun, Martin, Khalaph, Moneeb, Nölker, Georg, Sommer, Philipp, Sohns, Christian
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8777824/
https://www.ncbi.nlm.nih.gov/pubmed/35050226
http://dx.doi.org/10.3390/jcdd9010016
_version_ 1784637164182568960
author Guckel, Denise
Lucas, Philipp
Isgandarova, Khuraman
El Hamriti, Mustapha
Bergau, Leonard
Fink, Thomas
Sciacca, Vanessa
Imnadze, Guram
Braun, Martin
Khalaph, Moneeb
Nölker, Georg
Sommer, Philipp
Sohns, Christian
author_facet Guckel, Denise
Lucas, Philipp
Isgandarova, Khuraman
El Hamriti, Mustapha
Bergau, Leonard
Fink, Thomas
Sciacca, Vanessa
Imnadze, Guram
Braun, Martin
Khalaph, Moneeb
Nölker, Georg
Sommer, Philipp
Sohns, Christian
author_sort Guckel, Denise
collection PubMed
description Cryoballoon (CB)-guided pulmonary vein isolation (PVI) represents a cornerstone in the treatment of atrial fibrillation (AF). Recently, a novel balloon-guided single shot device (POLARx, Boston Scientific) was designed. Our study aimed to compare the efficacy, safety and characteristics of the novel CB system with the established one (Arctic Front Advance (Pro), AFA, Medtronic). A total number of 596 patients undergoing CB-guided ablation for AF were included. 65 patients (65.0 ± 11.6, 31% female) undergoing PVI with the POLARx were compared to a cohort of 531 consecutive patients (63.0 ± 27.9, 25% female) treated with AFA. Acute PVI was achieved in all patients (n = 596, 100%). Total procedure duration (POLARx 113.3 ± 23.2 min, AFA 100.9 ± 21.3 min; p < 0.001) and fluoroscopy time (POLARx 10.5 ± 5.9 min, AFA 4.8 ± 3.6 min; p < 0.001) were significantly longer in the POLARx group. The POLARx balloon achieved significantly lower nadir temperatures (POLARx −57.7 ± 0.9 °C, AFA −45.1 ± 2.6 °C; p < 0.001) and a significantly higher percentage of pulmonary veins successfully isolated with the first freeze (p = 0.027 *). One major complication occurred in the POLARx (2%) and three (1%) in the AFA group. Both ablation systems are comparably safe and effective. AF ablation utilizing the POLARx system is associated with longer procedure and fluoroscopy times as well as lower nadir temperatures.
format Online
Article
Text
id pubmed-8777824
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-87778242022-01-22 News from the Cold Chamber: Clinical Experiences of POLARx versus Arctic Front Advance for Single-Shot Pulmonary Vein Isolation Guckel, Denise Lucas, Philipp Isgandarova, Khuraman El Hamriti, Mustapha Bergau, Leonard Fink, Thomas Sciacca, Vanessa Imnadze, Guram Braun, Martin Khalaph, Moneeb Nölker, Georg Sommer, Philipp Sohns, Christian J Cardiovasc Dev Dis Article Cryoballoon (CB)-guided pulmonary vein isolation (PVI) represents a cornerstone in the treatment of atrial fibrillation (AF). Recently, a novel balloon-guided single shot device (POLARx, Boston Scientific) was designed. Our study aimed to compare the efficacy, safety and characteristics of the novel CB system with the established one (Arctic Front Advance (Pro), AFA, Medtronic). A total number of 596 patients undergoing CB-guided ablation for AF were included. 65 patients (65.0 ± 11.6, 31% female) undergoing PVI with the POLARx were compared to a cohort of 531 consecutive patients (63.0 ± 27.9, 25% female) treated with AFA. Acute PVI was achieved in all patients (n = 596, 100%). Total procedure duration (POLARx 113.3 ± 23.2 min, AFA 100.9 ± 21.3 min; p < 0.001) and fluoroscopy time (POLARx 10.5 ± 5.9 min, AFA 4.8 ± 3.6 min; p < 0.001) were significantly longer in the POLARx group. The POLARx balloon achieved significantly lower nadir temperatures (POLARx −57.7 ± 0.9 °C, AFA −45.1 ± 2.6 °C; p < 0.001) and a significantly higher percentage of pulmonary veins successfully isolated with the first freeze (p = 0.027 *). One major complication occurred in the POLARx (2%) and three (1%) in the AFA group. Both ablation systems are comparably safe and effective. AF ablation utilizing the POLARx system is associated with longer procedure and fluoroscopy times as well as lower nadir temperatures. MDPI 2022-01-08 /pmc/articles/PMC8777824/ /pubmed/35050226 http://dx.doi.org/10.3390/jcdd9010016 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Guckel, Denise
Lucas, Philipp
Isgandarova, Khuraman
El Hamriti, Mustapha
Bergau, Leonard
Fink, Thomas
Sciacca, Vanessa
Imnadze, Guram
Braun, Martin
Khalaph, Moneeb
Nölker, Georg
Sommer, Philipp
Sohns, Christian
News from the Cold Chamber: Clinical Experiences of POLARx versus Arctic Front Advance for Single-Shot Pulmonary Vein Isolation
title News from the Cold Chamber: Clinical Experiences of POLARx versus Arctic Front Advance for Single-Shot Pulmonary Vein Isolation
title_full News from the Cold Chamber: Clinical Experiences of POLARx versus Arctic Front Advance for Single-Shot Pulmonary Vein Isolation
title_fullStr News from the Cold Chamber: Clinical Experiences of POLARx versus Arctic Front Advance for Single-Shot Pulmonary Vein Isolation
title_full_unstemmed News from the Cold Chamber: Clinical Experiences of POLARx versus Arctic Front Advance for Single-Shot Pulmonary Vein Isolation
title_short News from the Cold Chamber: Clinical Experiences of POLARx versus Arctic Front Advance for Single-Shot Pulmonary Vein Isolation
title_sort news from the cold chamber: clinical experiences of polarx versus arctic front advance for single-shot pulmonary vein isolation
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8777824/
https://www.ncbi.nlm.nih.gov/pubmed/35050226
http://dx.doi.org/10.3390/jcdd9010016
work_keys_str_mv AT guckeldenise newsfromthecoldchamberclinicalexperiencesofpolarxversusarcticfrontadvanceforsingleshotpulmonaryveinisolation
AT lucasphilipp newsfromthecoldchamberclinicalexperiencesofpolarxversusarcticfrontadvanceforsingleshotpulmonaryveinisolation
AT isgandarovakhuraman newsfromthecoldchamberclinicalexperiencesofpolarxversusarcticfrontadvanceforsingleshotpulmonaryveinisolation
AT elhamritimustapha newsfromthecoldchamberclinicalexperiencesofpolarxversusarcticfrontadvanceforsingleshotpulmonaryveinisolation
AT bergauleonard newsfromthecoldchamberclinicalexperiencesofpolarxversusarcticfrontadvanceforsingleshotpulmonaryveinisolation
AT finkthomas newsfromthecoldchamberclinicalexperiencesofpolarxversusarcticfrontadvanceforsingleshotpulmonaryveinisolation
AT sciaccavanessa newsfromthecoldchamberclinicalexperiencesofpolarxversusarcticfrontadvanceforsingleshotpulmonaryveinisolation
AT imnadzeguram newsfromthecoldchamberclinicalexperiencesofpolarxversusarcticfrontadvanceforsingleshotpulmonaryveinisolation
AT braunmartin newsfromthecoldchamberclinicalexperiencesofpolarxversusarcticfrontadvanceforsingleshotpulmonaryveinisolation
AT khalaphmoneeb newsfromthecoldchamberclinicalexperiencesofpolarxversusarcticfrontadvanceforsingleshotpulmonaryveinisolation
AT nolkergeorg newsfromthecoldchamberclinicalexperiencesofpolarxversusarcticfrontadvanceforsingleshotpulmonaryveinisolation
AT sommerphilipp newsfromthecoldchamberclinicalexperiencesofpolarxversusarcticfrontadvanceforsingleshotpulmonaryveinisolation
AT sohnschristian newsfromthecoldchamberclinicalexperiencesofpolarxversusarcticfrontadvanceforsingleshotpulmonaryveinisolation